Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how he felt the multidisciplinary nature of the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®) was useful for future practice. Humphrey also talked about utilizing tumor boards where clinicians from different departments can discuss current topics.

Transcript:

One of the reasons I so enjoy this conference is the multidisciplinary nature. There’s directional learning and I’ve learned so much from my clinical colleagues today about their management based upon our diagnosis, for example. I think the same is true for when we present our diagnostic approach and how that diagnosis would influence them and their patient management. That multidisciplinary nature [for] taking care of patients with cancer, any cancer, is so vital.

I also appreciate that locally at Yale where we have weekly tumor boards, we have interactions amongst all of us including medical oncologists, urologist, interventional radiologists, diagnostic radiologists, and pathologists. Only by all of all of us having an input can we get a complete picture of the patient’s status at that point in time and have a vibrant discussion about treatment options. Depending upon the diagnosis and what radiologists and pathologists see at that point in time and in the patient’s care, it’s [providing] ongoing medical education for everyone while at the same time being practical in care of the patient.

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content